Myasthenia Gravis and COVID-19: Clinical Characteristics and Outcomes.
Myasthenia Gravis and COVID-19: Clinical Characteristics and Outcomes.
复制标题
DOI：
10.3389/fneur.2020.01053
复制
发表时间：
2020
影响因子：
3.4
通讯作者：
Zanoteli E
中科院分区：
文献类型：
--
作者：
Camelo-Filho AE;Silva AMS;Estephan EP;Zambon AA;Mendonça RH;Souza PVS;Pinto WBVR;Oliveira ASB;Dangoni-Filho I;Pouza AFP;Valerio BCO;Zanoteli E
重症肌无力（MG）是一种自身免疫性神经肌肉疾病，可能是严重COVID-19的风险因素。我们在巴西圣保罗的四家医院对15名连续的成年MG患者进行了一项观察性回顾性研究。大多数因COVID-19住院的MG患者病程严重：87%被送入重症监护室，73%需要机械通气，30%死亡。使用免疫球蛋白和血浆置换程序是安全的。免疫抑制治疗似乎与更好的结果相关，因为它可能起保护作用。
Myasthenia gravis (MG), an autoimmune neuromuscular disorder, may be a risk factor for severe COVID-19. We conducted an observational retrospective study with 15 consecutive adult MG patients admitted with COVID-19 at four hospitals in São Paulo, Brazil. Most patients with MG hospitalized for COVID-19 had severe courses of the disease: 87% were admitted in the intensive care unit, 73% needed mechanical ventilation, and 30% died. Immunoglobulin use and the plasma exchange procedure were safe. Immunosuppressive therapy seems to be associated with better outcomes, as it might play a protective role.
登录
查看更多内容
影响因子：
9.9
作者：
Romero-Sanchez, Carlos Manuel;Diaz-Maroto, Inmaculada;Segura, Tomas
通讯作者：
Segura, Tomas
影响因子：
3.3
作者：
Ramaswamy, Swathi Beladakere;Govindarajan, Raghav
通讯作者：
Govindarajan, Raghav
DOI：
10.1001/jama.2020.6775
发表时间：
2020-01-01
期刊：
JAMA, Journal of the American Medical Association
影响因子：
--
作者：
Richardson, Safiya;Hirsch, Jamie S.;,
通讯作者：
,
影响因子：
3.4
作者：
Anand, Pria;Slama, Michael C. C.;Guidon, Amanda C.
通讯作者：
Guidon, Amanda C.
影响因子：
168.9
作者：
Zhou, Fei;Yu, Ting;Cao, Bin
通讯作者：
Cao, Bin